Acquisition Opportunities Leap Therapeutics has been actively acquiring companies like Biopharmadive and Flame Biosciences, indicating a growth strategy that could present partnership or acquisition opportunities for related businesses looking to expand their portfolios or enter new markets.
Asia Expansion With a strategic agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia, Leap Therapeutics is expanding its presence in the Asian market. This presents an opportunity for partnerships with local companies or distributors in the region.
Clinical Studies & Collaborations The initiation of the randomized controlled Part B of the DeFianCe study of DKN-01 in colorectal cancer patients suggests an ongoing focus on clinical research and partnerships. Companies offering complementary services or products could explore collaboration opportunities for mutual benefit.
Key Director Appointment The appointment of Monica Bertagnolli, MD, as the Director of the National Cancer Institute presents a networking opportunity for businesses in the oncology space. Leveraging relationships with key personnel like Dr. Bertagnolli could lead to potential collaborations or knowledge sharing.
Companion Diagnostics Development The partnership between Leica Biosystems and Leap Therapeutics to develop a companion diagnostic for Dickkopf-related protein 1 (DKK1) indicates a focus on precision medicine. Companies in the diagnostics or personalized medicine sector could explore partnership opportunities in this niche area.
Leap Therapeutics uses 8 technology products and services including Microsoft Excel, Prototype, RequireJS, and more. Explore Leap Therapeutics's tech stack below.
| Leap Therapeutics Email Formats | Percentage |
| FLast@leaptx.com | 49% |
| Last@leaptx.com | 2% |
| FLast@leaptx.com | 49% |
Biotechnology ResearchMassachusetts, United States11-50 Employees
Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via http://www.investors.leaptx.com.
Company Overview
Media & News
Funding & FinancialsLeap Therapeutics has raised a total of $40M of funding over 10 rounds. Their latest funding round was raised on Apr 10, 2024 in the amount of $40M.
Leap Therapeutics's revenue is in the range of $10M
Funding & FinancialsLeap Therapeutics has raised a total of $40M of funding over 10 rounds. Their latest funding round was raised on Apr 10, 2024 in the amount of $40M.
Leap Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com